Skip to content

Glaukos GKOS EV / sales

EV / sales at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
6.5×+1.8×
AbbVie logo
AbbVieABBV
7.5×+1.0×
Boston Scientific logo
Boston ScientificBSX
-1.5×
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
3.6×-1.2×
Exelixis logo
ExelixisEXEL
4.7×+0.3×

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Calculated from Glaukos’s reported figures.

Based on the most recent quarter.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's EV / sales?
Glaukos (GKOS) reported EV / sales of 11.3× in Q1 2026.
How has Glaukos's EV / sales changed year-over-year?
Glaukos's EV / sales decreased by 17.5% year-over-year, from 13.7× to 11.3×.
What is the long-term trend for Glaukos's EV / sales?
Over 5 years (2020 to 2025), Glaukos's EV / sales has grown at a -3.9% compound annual growth rate (CAGR), from 15.6× to 12.8×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.